The Non-Steroidal FXR Agonist Cilofexor Improves Portal Hypertension and Reduces Hepatic Fibrosis in a Rat NASH Model

The Non-Steroidal FXR Agonist Cilofexor Improves Portal Hypertension and Reduces Hepatic Fibrosis in a Rat NASH Model

Background: The farnesoid X receptor (FXR) influences hepatic metabolism, inflammation and liver fibrosis as key components of non-alcoholic steatohepatitis (NASH). We studied the effects of the non-steroidal FXR agonist cilofexor (formerly GS-9674) on portal pressure and fibrosis in experimental NA...

Full description

Bibliographic Details
Main Authors: Philipp Schwabl, Eva Hambruch, Grant R. Budas, Paul Supper, Michael Burnet, John T. Liles, Manfred Birkel, Ksenia Brusilovskaya, Philipp Königshofer, Markus Peck-Radosavljevic, William J. Watkins, Michael Trauner, David G. Breckenridge, Claus Kremoser, Thomas Reiberger
Format: Article
Language:English
Published: MDPI AG 2021-01-01
Series:Biomedicines
Subjects:
NASH
FXR
cilofexor
portal hypertension
fibrosis
rats
Online Access:https://www.mdpi.com/2227-9059/9/1/60

Internet

https://www.mdpi.com/2227-9059/9/1/60

Similar Items